98 related articles for article (PubMed ID: 14991868)
1. P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.
Fedoruk MN; Giménez-Bonafé P; Guns ES; Mayer LD; Nelson CC
Prostate; 2004 Apr; 59(1):77-90. PubMed ID: 14991868
[TBL] [Abstract][Full Text] [Related]
2. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
3. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
4. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activation of the androgen receptor by bombesin and low-dose androgen.
Dai J; Shen R; Sumitomo M; Stahl R; Navarro D; Gershengorn MC; Nanus DM
Clin Cancer Res; 2002 Jul; 8(7):2399-405. PubMed ID: 12114445
[TBL] [Abstract][Full Text] [Related]
6. Androgen regulation of micro-RNAs in prostate cancer.
Waltering KK; Porkka KP; Jalava SE; Urbanucci A; Kohonen PJ; Latonen LM; Kallioniemi OP; Jenster G; Visakorpi T
Prostate; 2011 May; 71(6):604-14. PubMed ID: 20945501
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor-dependent PSA expression in androgen-independent prostate cancer cells does not involve androgen receptor occupancy of the PSA locus.
Jia L; Coetzee GA
Cancer Res; 2005 Sep; 65(17):8003-8. PubMed ID: 16140973
[TBL] [Abstract][Full Text] [Related]
8. Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer.
Jacob S; Nayak S; Fernandes G; Barai RS; Menon S; Chaudhari UK; Kholkute SD; Sachdeva G
Endocr Relat Cancer; 2014 Jun; 21(3):473-86. PubMed ID: 24812058
[TBL] [Abstract][Full Text] [Related]
9. Changes of androgen receptor and insulin-like growth factor-1 in LNCaP prostate cancer cells treated with sex hormones and flutamide.
Tong da Y; Wen XQ; Jin Y; Liu ZW; Sun HY; Zhou FJ; Wu XY
Asian Pac J Cancer Prev; 2010; 11(6):1805-9. PubMed ID: 21338237
[TBL] [Abstract][Full Text] [Related]
10. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
Zhao XY; Ly LH; Peehl DM; Feldman D
Endocrinology; 1997 Aug; 138(8):3290-8. PubMed ID: 9231780
[TBL] [Abstract][Full Text] [Related]
11. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
[TBL] [Abstract][Full Text] [Related]
12. Dihydrotestosterone interacts with EGFR/MAPK signalling and modulates EGFR levels in androgen receptor-positive LNCaP prostate cancer cells.
Mukherjee B; Mayer D
Int J Oncol; 2008 Sep; 33(3):623-9. PubMed ID: 18695894
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of androgenic regulation by brefeldin A in androgen-responsive prostate cancer cells.
Alexander B; Fishman AI; Green D; Choudhury MS; Konno S
Urol Oncol; 2013 Jan; 31(1):104-9. PubMed ID: 21795077
[TBL] [Abstract][Full Text] [Related]
14. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells.
Bruckheimer EM; Spurgers K; Weigel NL; Logothetis C; McDonnell TJ
J Urol; 2003 Apr; 169(4):1553-7. PubMed ID: 12629413
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
17. Androgen up-regulates epidermal growth factor receptor expression and binding affinity in PC3 cell lines expressing the human androgen receptor.
Brass AL; Barnard J; Patai BL; Salvi D; Rukstalis DB
Cancer Res; 1995 Jul; 55(14):3197-203. PubMed ID: 7606741
[TBL] [Abstract][Full Text] [Related]
18. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of DHEA and DHT on gene expression in human LNCaP prostate cancer cells.
Steele VE; Arnold JT; Lei H; Izmirlian G; Blackman MR
Anticancer Res; 2006; 26(5A):3205-15. PubMed ID: 17094431
[TBL] [Abstract][Full Text] [Related]
20. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.
Saporita AJ; Ai J; Wang Z
Prostate; 2007 Apr; 67(5):509-20. PubMed ID: 17221841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
